ICAM1 and dry eye syndrome: According to the Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop [1], dry eye syndrome is “a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface.” Unlike conventional therapies that primarily manage the symptoms, LIF is designed to inhibit interaction between lymphocyte function-associated antigen 1 (LFA-1) and intercellular adhesion molecule 1 (ICAM-1).